Rachel Tsunemoto Hislop
Director/Board Member at Abilita Therapeutics, Inc.
Profile
Rachel Tsunemoto Hislop is currently working as a Director at Abilita Therapeutics, Inc. and as a Principal at Two Bear Capital Operations LLC since 2020.
She completed her undergraduate degree from Massachusetts Institute of Technology.
Rachel Tsunemoto Hislop active positions
Companies | Position | Start |
---|---|---|
Two Bear Capital Operations LLC
Two Bear Capital Operations LLC Investment ManagersFinance Two Bear Capital Operations LLC (Two Bear Capital) is venture capital firm founded in 2019 by Mike Goguen. The firm is headquartered in Whitefish, Montana. | Private Equity Investor | 31/12/2019 |
Abilita Therapeutics, Inc.
Abilita Therapeutics, Inc. BiotechnologyHealth Technology Abilita Therapeutics, Inc. is a biotechnology company that focuses on discovering and developing drugs that target challenging human membrane proteins with high medical impact, such as GPCRs, ion channels, and transporters. The company is based in San Diego, CA. The company's internal drug discovery pipeline is focused on treating cancer and chronic pain. Abilita Bios EMP™ platform fuels research collaborations with pharmaceutical and biotech partners. The company was founded in 2014 by Mauro Mileni, who has been the CEO since 2014. | Director/Board Member | - |
Training of Rachel Tsunemoto Hislop
Massachusetts Institute of Technology | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Two Bear Capital Operations LLC
Two Bear Capital Operations LLC Investment ManagersFinance Two Bear Capital Operations LLC (Two Bear Capital) is venture capital firm founded in 2019 by Mike Goguen. The firm is headquartered in Whitefish, Montana. | Finance |
Abilita Therapeutics, Inc.
Abilita Therapeutics, Inc. BiotechnologyHealth Technology Abilita Therapeutics, Inc. is a biotechnology company that focuses on discovering and developing drugs that target challenging human membrane proteins with high medical impact, such as GPCRs, ion channels, and transporters. The company is based in San Diego, CA. The company's internal drug discovery pipeline is focused on treating cancer and chronic pain. Abilita Bios EMP™ platform fuels research collaborations with pharmaceutical and biotech partners. The company was founded in 2014 by Mauro Mileni, who has been the CEO since 2014. | Health Technology |
- Stock Market
- Insiders
- Rachel Tsunemoto Hislop